Fmr LLC continued to hold its stake in shares of Enzymotec Ltd. (NASDAQ:ENZY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,900 shares of the biotechnology company’s stock at the close of the second quarter. Fmr LLC owned approximately 0.37% of Enzymotec worth $688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several brokerages have commented on ENZY. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine raised Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reissued a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research report on Thursday, October 19th. Finally, Wells Fargo & Company raised their price objective on Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research report on Monday, October 30th. Four analysts have rated the stock with a hold rating, The stock currently has an average rating of “Hold” and a consensus target price of $11.75.

Enzymotec Ltd. (NASDAQ:ENZY) opened at $11.80 on Friday. Enzymotec Ltd. has a 52-week low of $5.20 and a 52-week high of $12.35.

Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.15). The firm had revenue of $13.00 million for the quarter, compared to analysts’ expectations of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.04 EPS. analysts forecast that Enzymotec Ltd. will post 0.01 EPS for the current year.

WARNING: “Fmr LLC Has $688,000 Holdings in Enzymotec Ltd. (ENZY)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Want to see what other hedge funds are holding ENZY? Visit to get the latest 13F filings and insider trades for Enzymotec Ltd. (NASDAQ:ENZY).

Institutional Ownership by Quarter for Enzymotec (NASDAQ:ENZY)

Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.